Amgen reorganized its executive structure to place James Bradner over a newly combined "R&D, AI and Data" function and appointed a new chief technology officer, embedding artificial intelligence at the operational center of the company's drug development engine.
The structural consolidation — rather than a standalone AI team alongside R&D — reflects a calculated bet on integration over experimentation. Big Pharma is no longer piloting AI. It is building around it.
AI-native biotechs are moving in parallel. Rakovina Therapeutics presented preclinical data at the 2026 AACR Annual Meeting on two programs using generative AI platforms to attack targets that have historically resisted conventional approaches.1 Both programs are designed to address poor CNS penetrance and the toxicity burdens that have constrained existing oncology regimens.1
CNS penetrance is a structural barrier in oncology. Brain metastasis remains one of the most urgent and therapeutically underserved challenges in cancer care.2 Most approved therapies fail to cross the blood-brain barrier at therapeutic concentrations, leaving patients with limited options after metastatic spread.
Rakovina's dual ATR-mTOR program targets two intersecting DNA-damage response pathways simultaneously. The generative AI approach allows candidate optimization across both targets without the additive toxicity typically associated with combination regimens.1
The regulatory calendar is compressing decision timelines. Crinetics Pharmaceuticals secured European Commission approval for PALSONIFY (paltusotine), an oral therapy for acromegaly. Phase 3 data showed no serious adverse events in the randomized controlled portion of the trial, with diarrhea, abdominal pain, nausea, and abdominal discomfort as the most frequently reported reactions.3
Approvals like PALSONIFY illustrate how AI-assisted pipeline management translates into regulatory velocity. Oral formulations replacing injectable standards of care — a recurring theme in endocrinology and oncology — require precision tolerability data that generative platforms accelerate.
The convergence is clear: large-cap pharma is restructuring capital allocation and leadership hierarchies around AI, while smaller biotechs deploy generative platforms as a first-principles approach to historically intractable biology. Companies that institutionalize AI now gain compounding advantages as platforms accelerate candidate identification, reduce combination toxicity, and shorten the path to regulatory submission.
Amgen's structural move sets an organizational template. Others will follow or fall behind.
